Agenix antibody in US diagnostic test
Thursday, 17 February, 2005
AGEN Biomedical, a subsidiary of Brisbane-based biotech Agenix (ASX: AGX), is set to receive royalties from a newly launched test developed by US diagnostics company Biosite that uses AGEN's D-Dimer antibody.
Biosite's Triage D-Dimer diagnostic is a point-of-care diagnostic for the assessment and evaluation of patients suspected of having thromboembolic events including pulmonary embolism and deep vein thrombosis. The ELISA-based test measures five biomarkers including D-Dimer, and provides results within 15 minutes. AGEN licensed the D-Dimer antibody and associated IP to Biosite in November 2003.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
